MAB logo

Mabion S.A. Stock Price

WSE:MAB Community·zł133.2m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

MAB Share Price Performance

zł8.24
-1.36 (-14.17%)
zł8.24
-1.36 (-14.17%)
Price zł8.24

MAB Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Mediocre balance sheet with very low risk.

2 Risks
0 Rewards

Mabion S.A. Key Details

zł14.8m

Revenue

zł47.3m

Cost of Revenue

-zł32.5m

Gross Profit

zł26.8m

Other Expenses

-zł59.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-3.67
-219.67%
-400.36%
0.6%
View Full Analysis

About MAB

Founded
2007
Employees
210
CEO
Krzysztof Kaczmarczyk
WebsiteView website
www.mabion.eu

Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation of the necessary documentation. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.

Recent MAB News & Updates

Recent updates

No updates